Clinical medicine profile
Mitozantrone
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Only physicians experienced in cancer chemotherapy should use it
- increased incidence of infections
- to reduce the dose in case of impaired hepatic function
- severe myelosuppression with resulting infection or bleeding may occur
- cardiac function should be monitored regularly.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
IV 100-120mg/m2, given on Day 1 of cycle or divided into 2 doses and given on Day 1 and Day 8. It is repeated every 2128 days for 6 cycles [in combination with other chemotherapy agents]. Consult specialist literature for further information.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Acute myeloid (myelogenous, nonlymphocytic) leukemia in adults
- hormone-refractory prostate cancer.
- (In combination with other chemotherapeutic agents) Clinical selection for Mitozantrone should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Therapeutic agent (verify pharmacological class).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Myelosuppression
- cardiac toxicity and congestive heart failure
- triad of back pain
- flushing
- and chest tightness
- increased appetite
- dysphagia
- GI haemorrhage
- gastritis
- stomatitis
- nausea and vomiting
- gingival bleeding
- hemorrhoids
- diarrhea
Drug interactions
Open multi-drug checker ↗- It is a synthetic anthracenedione antineoplastic agent derived from the anthraquinone dye ametantrone and structurally related to the anthracyclines doxorubicin and daunorubicin.
Mechanism & disposition
It is thought to act by binding to DNA by intercalation between base and a non-intercalative electrostatic resulting in inhibition of DNA and RNA synthesis.
Read complete mechanism
It is thought to act by binding to DNA by intercalation between base and a non-intercalative electrostatic resulting in inhibition of DNA and RNA synthesis. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.